Caliper Life Sciences
combines microfluidics, liquid handling and laboratory automation to
deliver research tools for drug discovery and development, and genomics
and proteomics laboratories. The company uses direct, indirect
distribution, and partnership channels to increase penetration of its
products and technologies. Caliper’s partnership distribution channel
is core to Caliper’s business strategy and complimentary to its direct
sales and distribution network activities.
Using their partnership channel, Caliper has participated in the
launch of many products, including lab systems with Agilent, Bio-Rad
and Affymetrix. Recently, Affymetrix and Predicant Biosciences have
licensed a portion of Caliper’s microfluidics patent estate for use in
proteomics and GeneChip analysis.
Caliper’s in house products include the LabChip 3000 Drug Discovery
system, used by 75% of the largest 15 pharmaceutical companies as a
tool in their screening effort. The number one application of the
system is kinase profiling. LabChip assays are separations-based, so
the quality of results exceeds what is achievable in homogenous,
well-based assays. Few false positives, few false negatives and
analytical quality reproducibility are the reasons cited for using the
Caliper also manufactures and markets high volume liquid handling
workstations, more compact assay workstations, and an Automated
Electrophoresis system. In 2006 the company introduced the IVIS
Spectrum System which provides optical imaging of deep tissues. The
system can be used to analyze laboratory animals.
Caliper gained access
to the technology in their acquisition of Xenogen in August 2006.
In 2005, Caliper acquired NovaScreen Biosciences. NovaScreen offers
drug discovery and development services to improve productivity while
reducing costs and accelerating the pace of pharmaceutical research and
development. NovaScreen offers over 650 in vitro screening assays and
assay development services to major pharmaceutical, biotechnology and
educational institutions worldwide. In addition, NovaScreen works with
government agencies such as the National Institutes of Health [NIH] and
the National Institute of Allergy and Infectious Diseases [NIAID] and
National Institute on Drug Abuse [NIDA].
Caliper has met or exceeded financial guidance for 13 consecutive
quarters. 25% of their 2007 revenues are coming from new products with
long term growth prospects on the order of 10-12% per year. They expect
revenue growth of approximately 8-12% over the next few years. Caliper
is cash flow positive from operations, excluding restructuring payments.
Thank you for your interest in Seeking Alpha PRO We look forward to contacting you shortly for a conversation.
Our PRO subscription service was created for fund managers, and the cost of the product is
prohibitive for most individual investors.
If you are an investment professional with over $1M AUM and received this message
in error, click here and you will be contacted shortly.
Thank you for your interest in Seeking Alpha PRO We look forward to contacting you when we have an individual investor product ready!